• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

静脉输注和肌内注射后头孢曲松的药代动力学

Pharmacokinetics of ceftriaxone after intravenous infusion and intramuscular injection.

作者信息

Scully B E, Fu K P, Neu H C

出版信息

Am J Med. 1984 Oct 19;77(4C):112-6.

PMID:6093511
Abstract

The pharmacokinetics of ceftriaxone were evaluated in eight adults after doses of 1 g administered by intravenous infusion and 1 and 0.5 g administered by intramuscular injection. Mean peak plasma concentrations were 168 micrograms/ml for 1 g given intravenously, 81 micrograms/ml for 1 g given intramuscularly, and 46 micrograms/ml for 0.5 g intramuscularly. Plasma concentrations were similar by both high pressure liquid chromatographic and microbiologic methods. The plasma half-lives were 7.6 and 8.3 hours, respectively, for the intravenous infusion and intramuscular injection. Plasma concentrations were equal for the 1 g intravenous and intramuscular routes by 2.5 hours. Plasma concentrations exceeded the minimal inhibitory concentrations (MICs) of most aerobic gram-positive and gram-negative organisms with the exception of Pseudomonas aeruginosa and Acinetobacter species for 24 hours. Urinary concentrations exceeded 100 micrograms/ml for 24 hours for the 1-g doses and for 12 hours for the 0.5-g dose. Urinary recovery of ceftriaxone within 24 hours was 40 percent for intravenous infusion and 33 and 34 percent for the intramuscular injection. A single 1-g dose daily will exceed the MICs of most staphylococcal and streptococcal species and Enterobacteriaceae for 12 to 24 hours.

摘要

对8名成年人进行了头孢曲松的药代动力学评估,静脉输注1g剂量以及肌内注射1g和0.5g剂量后,静脉注射1g的平均血浆峰浓度为168微克/毫升,肌内注射1g的为81微克/毫升,肌内注射0.5g的为46微克/毫升。通过高压液相色谱法和微生物学法测得的血浆浓度相似。静脉输注和肌内注射的血浆半衰期分别为7.6小时和8.3小时。静脉注射和肌内注射1g剂量时,2.5小时后血浆浓度相等。除铜绿假单胞菌和不动杆菌属外,血浆浓度超过大多数需氧革兰氏阳性和革兰氏阴性菌的最低抑菌浓度(MICs)达24小时。1g剂量时尿浓度超过100微克/毫升达24小时,0.5g剂量时达12小时。静脉输注24小时内头孢曲松的尿回收率为40%,肌内注射为33%和34%。每日单次1g剂量将超过大多数葡萄球菌、链球菌属和肠杆菌科细菌的MICs达12至24小时。

相似文献

1
Pharmacokinetics of ceftriaxone after intravenous infusion and intramuscular injection.静脉输注和肌内注射后头孢曲松的药代动力学
Am J Med. 1984 Oct 19;77(4C):112-6.
2
Crossover study of the pharmacokinetics of ceftriaxone administered intravenously or intramuscularly to healthy volunteers.头孢曲松静脉注射或肌肉注射于健康志愿者的药代动力学交叉研究。
Antimicrob Agents Chemother. 1983 Nov;24(5):812-4. doi: 10.1128/AAC.24.5.812.
3
Pharmacokinetics of ceftriaxone in subjects with renal insufficiency.头孢曲松在肾功能不全患者中的药代动力学。
Clin Pharm. 1985 Mar-Apr;4(2):177-81.
4
Variability of ceftriaxone pharmacokinetics in hospitalized patients with severe infections.
Am J Med. 1984 Oct 19;77(4C):59-62.
5
Pharmacokinetic profile of ceftriaxone in man.头孢曲松在人体内的药代动力学特征。
Am J Med. 1984 Oct 19;77(4C):17-25.
6
Pharmacokinetics of cefotaxime in sheep.头孢噻肟在绵羊体内的药代动力学
Am J Vet Res. 1983 Aug;44(8):1488-91.
7
Pharmacokinetics of cefotaxime in the domestic cat.
Am J Vet Res. 1986 Jan;47(1):86-8.
8
[Clinical study on cefmenoxime (CMX) in urology].[头孢甲肟(CMX)在泌尿外科的临床研究]
Hinyokika Kiyo. 1983 Jan;29(1):95-103.
9
Pharmacokinetic profile of cefotaxime in goats.头孢噻肟在山羊体内的药代动力学特征
Res Vet Sci. 1990 Jul;49(1):34-8.
10
[Kinetics of cefotaxime in healthy subjects (author's transl)].健康受试者中头孢噻肟的动力学(作者译)
Nouv Presse Med. 1981 Feb 26;10(8):559-63.

引用本文的文献

1
Targeting complement C3/C3aR pathway restores rejuvenation factor PF4 and mitigates neurocognitive impairments in age-related perioperative neurocognitive disorders.靶向补体C3/C3aR通路可恢复年轻化因子PF4,并减轻与年龄相关的围手术期神经认知障碍中的神经认知损伤。
Mol Psychiatry. 2025 Jul 14. doi: 10.1038/s41380-025-03103-z.
2
Prehospital antibiotics and intravenous fluids for patients with sepsis: protocol for a 2×2 factorial randomised controlled trial.脓毒症患者的院前抗生素和静脉输液治疗:一项2×2析因随机对照试验方案
BMJ Open. 2025 May 27;15(5):e104257. doi: 10.1136/bmjopen-2025-104257.
3
Transcatheter aortic valve implantation (TAVI) prostheses - biofilm formation and antibiotic effects.
经导管主动脉瓣植入术(TAVI)假体——生物膜形成及抗生素作用
Biofilm. 2024 Nov 1;8:100236. doi: 10.1016/j.bioflm.2024.100236. eCollection 2024 Dec.
4
Modeling the bacterial dynamics in the gut microbiota following an antibiotic-induced perturbation.模拟抗生素诱导扰动后肠道微生物群中的细菌动态。
CPT Pharmacometrics Syst Pharmacol. 2022 Jul;11(7):906-918. doi: 10.1002/psp4.12806. Epub 2022 May 18.
5
Chronic wound isolates and their minimum inhibitory concentrations against third generation cephalosporins at a tertiary hospital in Uganda.乌干达一家三级医院慢性创面分离菌及其对第三代头孢菌素的最低抑菌浓度。
Sci Rep. 2022 Jan 24;12(1):1195. doi: 10.1038/s41598-021-04722-6.
6
Resistance pattern of infected chronic wound isolates and factors associated with bacterial resistance to third generation cephalosporins at Mbarara Regional Referral Hospital, Uganda.乌干达姆巴拉拉地区转诊医院感染性慢性伤口分离株的耐药模式及与第三代头孢菌素耐药相关的因素。
PLoS One. 2021 Dec 16;16(12):e0261264. doi: 10.1371/journal.pone.0261264. eCollection 2021.
7
Once-daily ceftriaxone out-patient therapy for superficial wound infection following major orthopaedic operation.
Eur J Orthop Surg Traumatol. 1996 May;6(2):115-7. doi: 10.1007/BF00568328.
8
The pharmacokinetics of ceftriaxone based on population pharmacokinetics and the prediction of efficacy in Japanese adults.基于群体药代动力学的头孢曲松在日本成年人中的药代动力学及疗效预测
Eur J Drug Metab Pharmacokinet. 2009 Apr-Jun;34(2):107-15. doi: 10.1007/BF03191159.
9
Clinical trial of the outpatient management of pyelonephritis in pregnancy.妊娠期肾盂肾炎门诊管理的临床试验
Infect Dis Obstet Gynecol. 1995;3(2):50-5. doi: 10.1155/S1064744995000305.
10
Ceftriaxone: an update of its use in the management of community-acquired and nosocomial infections.头孢曲松:其在社区获得性感染和医院感染管理中应用的最新情况
Drugs. 2002;62(7):1041-89. doi: 10.2165/00003495-200262070-00005.